- April 24, 2018
- Posted by: PharmaScroll
- Category:
As per a new study conducted and to be presented and AAN 2018, in the adults with MS who switched from any injectable DMT to fingolimod, the risk of relapses was significantly lower as compared to the risk in the patients switching to any other injectable DMT.
The study was aimed at comparing relapse rates of patients switching from an injectable DMT to fingolimod against those of patients switching from one injectable DMT to another injectable DMT in a real-world setting.
A retrospective cohort study was conducted using a large US claims database. Eligible patients were adults diagnosed with MS treated with an injectable DMT for ≥1 year between 7/1/2011 and 6/30/2015 before switching to either fingolimod or another injectable DMT. Demographics, clinical characteristics, and medication use were assessed during the baseline and follow-up periods. MS relapses in the baseline and follow-up periods were detected based on a validated claims-based algorithm. A negative binomial regression model with repeated measures estimated the incidence rate ratio of relapses over one year between the switchers to fingolimod and the injectable DMT cyclers.
Results of the Study:
Of 2,018 patients identified, 1,110 were switchers to fingolimod and 908 were injectable DMT cyclers. The cohorts were similar in age and gender, but more patients in the injectable DMT cyclers cohort had MS related symptoms and relapses in the baseline period. The negative binomial model indicated an incidence rate ratio of relapses of 0.78 (95% CI 0.61 −0.99, p-value = 0.04), a 22% risk reduction of relapses associated with switching to fingolimod instead of switching to another injectable DMT.
The study concluded that in a real-world study of U.S. adults with MS who switched from any injectable DMT to either fingolimod or to another injectable DMT, the risk of relapses was significantly lower for those switching to fingolimod. The study further highlighted that the results provide real-world evidence to support fingolimod as an alternative treatment for patients on injectable DMT when a change in therapy is clinically indicated.
About Pharmascroll:
Pharmascroll is a diligent business consulting and market research firm focused solely towards pharmaceutical markets. The company consults and researches in majorly chronic disease indications prevalent across the globe. The research conducted by Pharmascroll analysts is targeted to provide analytical and logical answers to the key business questions of the pharmaceutical and medical insights teams and to make better informed business decisions with the detailed relevant information available.
To read more news about Multiple Sclerosis, visit https://pharmascroll.com/news-category/multiple-sclerosis/
News Source: AAN 2018 website